Sun Pharmaceutical Industries Ltd. India’s largest drugmaker, reported a mixed set of numbers for the quarter ended March 2025. While revenue and operating performance remained healthy, net profit declined sharply year-on-year, missing analyst expectations.



The company's revenue increase 8.1% to ₹`12,958.8 compared to ₹11,982.9 crore in the previous year. A CNBC-TV18 poll had estimated a 9% increase in its revenue at ₹13,039.2 crore.



Net profit came in at ₹2,153.9 crore for Q4FY25, down 19% from ₹2,658.7 crore in the corresponding quarter last year. The Street had estimated a 10% increase in profit at ₹2,934 crore.



The pharma company's earnings before interest, taxes, depreciation and amortisation (EBITDA) was up 22.4% at ₹3,715.9 crore compared to ₹3,035.15 crore in the fourth quarter of the previous fiscal. The Street had pegged a 19% increase in its EBITDA at ₹3,618 crore.



The company's margin expanded to 28.7% from 25.3% in the year-ago period. A CNBC-TV18 poll had estimated the margin to be at 27.7% in the fourth quarter.

The company’s board of directors has recommended a final dividend of ₹5.50 per equity share for the financial year 2024–25, subject to shareholder approval at the upcoming annual general meeting.

Ahead of the earnings announcement, shares of Sun Pharma closed 0.52% lower at ₹1,722.65 on the BSE.

Also Read: Here's why VRL Logistics shares surged 13% during Thursday's trading session